Incyte Corporation (NASDAQ:INCY) Receives Consensus Rating of “Hold” from Analysts

Shares of Incyte Corporation (NASDAQ:INCY) have received a consensus recommendation of “Hold” from the twenty-one analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $104.00.

A number of equities research analysts have commented on INCY shares. Wells Fargo & Company reduced their price objective on Incyte from $107.00 to $101.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 11th. Wall Street Zen cut Incyte from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. Mizuho set a $121.00 price target on shares of Incyte and gave the company an “outperform” rating in a research note on Monday, December 8th. TD Cowen restated a “buy” rating on shares of Incyte in a report on Tuesday, January 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Incyte in a research note on Monday, March 9th.

Insider Activity at Incyte

In other news, EVP Mohamed Khairie Issa sold 10,856 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $109.07, for a total value of $1,184,063.92. Following the transaction, the executive vice president owned 66,132 shares in the company, valued at $7,213,017.24. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael James Morrissey sold 54,008 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $97.29, for a total transaction of $5,254,438.32. Following the transaction, the executive vice president directly owned 31,830 shares in the company, valued at $3,096,740.70. The trade was a 62.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 72,561 shares of company stock valued at $7,195,307. 17.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Incyte

Institutional investors have recently modified their holdings of the business. Elyxium Wealth LLC bought a new position in Incyte during the fourth quarter valued at $28,000. Smithfield Trust Co raised its stake in shares of Incyte by 135.0% in the fourth quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 162 shares during the period. Harbor Capital Advisors Inc. purchased a new position in shares of Incyte during the 3rd quarter valued at $26,000. Root Financial Partners LLC purchased a new position in shares of Incyte during the 3rd quarter valued at $28,000. Finally, University of Texas Texas AM Investment Management Co. bought a new position in shares of Incyte during the 4th quarter worth $35,000. 96.97% of the stock is owned by institutional investors.

Incyte Stock Up 0.6%

Incyte stock opened at $92.54 on Friday. The firm has a market cap of $18.42 billion, a price-to-earnings ratio of 14.44, a PEG ratio of 0.73 and a beta of 0.84. Incyte has a 52-week low of $53.56 and a 52-week high of $112.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.32. The firm has a 50 day moving average price of $101.78 and a two-hundred day moving average price of $96.48.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing the consensus estimate of $1.96 by ($0.16). The firm had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The company’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.43 earnings per share. Equities analysts predict that Incyte will post 4.86 EPS for the current year.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.